"Buzz on the Street" Show: Algernon (OTCQB: AGNPF) (CSE: AGN) to Manufacture Ifenprodil for COVID-19 | Financial Buzz

“Buzz on the Street” Show: Algernon (OTCQB: AGNPF) (CSE: AGN) to Manufacture Ifenprodil for COVID-19

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Algernon Appoints U.S. Company for cGMP Manufacturing of NP-120 (Ifenprodil) for COVID-19 Clinical Trials”

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) (CSE: AGN) a clinical stage pharmaceutical development company announces that it has awarded the contract to manufacture the active pharmaceutical ingredient for NP-120 (Ifenprodil), to U.S. based Cascade Chemistry. Algernon has made the decision to scale-up cGMP manufacturing of Ifenprodil to support its quickly evolving clinical program for acute lung injury (ALI), its urgent clinical focus on COVID-19 (Coronavirus), as well as its idiopathic pulmonary fibrosis (IPF) clinical program. Cascade Chemistry, based in Eugene Oregon, are specialists in chemical synthesis.

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and chronic cough.

Medical conditions are universally prevalent around the world, especially in areas where people lack access to proper healthcare. The most common forms of deadly medical conditions are coronary artery disease, cancers, diabetes, cirrhosis, and tuberculosis, according to Health Line. Even while many biotechnology companies are focusing on treatments, the number of medical cases are steadily growing every year. On the other hand, the demand to effectively treat or potentially eliminate these conditions is also growing. However, now companies within the industry are beginning to focus on therapeutic and diagnostic solutions such as red biotechnology, recombinant technology, and DNA sequencing. According to data compiled by Variant Market Research, the global biotechnology market is estimated to reach USD 726.8 Billion by 2025. Additionally, the market is expected to exhibit a CAGR of 8.1% from 2017 to 2025.

Other common medical conditions that are found around the world include lung diseases. For example, in 2010, lung diseases accounted for over 1 million deaths in the U.S., according to the National Heart, Lung, and Blood Institute. Lung diseases are primarily caused by family genetics, but can also result from allergies, being overweight, smoking, and exposure to pollutants. There are various classifications of lung diseases, such as diseases that affect the airway, air sacs, and blood vessels, but the concern over interstitial lung diseases has recently become more prevalent. Interstitial lung diseases (ILD) affect the interstitium, which is a microscopically thin, delicate lining between the lungs’ air sacs. The most common forms of ILDs are idiopathic pulmonary fibrosis (IPF) and sarcoidosis. IPFs cause the lung tissue to scar, changing the lungs’ ability to function properly. However, IPFs are just one of the biggest markets within the segment. There is currently no cure for IPFs, therefore, biotechnology companies continually develop and expand upon drugs for treatment. According to Technavio analysts, the global idiopathic pulmonary fibrosis market is expected to grow at a CAGR of 23.97% during the period from 2016 to 2020. “Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and is increasingly recognized. Prior to the advent of effective therapies, achieving an early diagnosis was arguably of little prognostic consequence given IPF was considered an untreatable and uniformly fatal disease,” according to research published on the U.S. National Library of Medicine. “The advent of new drug treatments has given hope for the future and raised the profile of IPF. International management guidelines highlight the critical role of radiology as part of an interstitial lung disease multidisciplinary team approach in reaching an accurate and early diagnosis of IPF.”

For more information, please visit: Algernon Pharmaceuticals Inc.

For more corporate news on Algernon Pharmaceuticals Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For algernon pharmaceuticals inc. financial and corporate news dissemination, FinancialBuzz.com expects to be compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.